Cargando…
Epidemiological Characteristics and Risk Factors of Methamphetamine—Associated Psychotic Symptoms
Objective: To explore the epidemiological characteristics and the risk factors for methamphetamine (MA)—associated psychotic symptoms among MA users in China. Methods: A cross-sectional study was conducted between April, 2012 and October, 2015 among individuals for whom MA was the principal drug of...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194209/ https://www.ncbi.nlm.nih.gov/pubmed/30369888 http://dx.doi.org/10.3389/fpsyt.2018.00489 |
_version_ | 1783364192808468480 |
---|---|
author | Su, Meng-Fan Liu, Mo-Xuan Li, Jin-Qiao Lappin, Julia M. Li, Su-xia Wu, Ping Liu, Zhi-Min Shi, Jie Lu, Lin Bao, Yanping |
author_facet | Su, Meng-Fan Liu, Mo-Xuan Li, Jin-Qiao Lappin, Julia M. Li, Su-xia Wu, Ping Liu, Zhi-Min Shi, Jie Lu, Lin Bao, Yanping |
author_sort | Su, Meng-Fan |
collection | PubMed |
description | Objective: To explore the epidemiological characteristics and the risk factors for methamphetamine (MA)—associated psychotic symptoms among MA users in China. Methods: A cross-sectional study was conducted between April, 2012 and October, 2015 among individuals for whom MA was the principal drug of use in a Compulsory Drug Detoxification Center in Beijing, Guangdong Province. Demographic, drug use and psychological characteristics were examined using a specifically-designed questionnaire, the Positive and Negative Syndrome Scale, Barratt Impulsive Scale, Hamilton Anxiety Scale and Beck Depression Inventory. Logistic regression was performed to explore the risk factors for MA-associated psychotic symptoms. Results: A total of 1685 participants were included. Participants were predominantly aged 30 or above, unemployed, and were unmarried Han Chinese men, with limited education. The duration of MA use was more than 3 months in 72.3%. 47.8% reported that the dose of MA use was ≥ 0.2 g per occasion of use. 11.5% had used two or more synthetic drugs. The prevalence of MA-associated psychotic symptoms was 17.0% among MA users during periods of abstinence. Multiple logistic regression analyses showed that a higher dose (≥0.2 g per time), a longer duration of MA use (>3 months) a history of heroin use and a history of tobacco use were associated with MA-associated psychotic symptoms, with adjusted odds ratios (ORs) of 1.96 (95% confidence interval [CI]: 1.40–2.76), 1.98 (95% CI: 1.33–2.96) and 2.45 (95% CI: 1.67–3.60), 1.78 (95% CI: 1.27–2.49) respectively. MA-associated psychotic symptoms were less common among married/cohabitating than unmarried (OR = 0.56; 95% CI: 0.39–0.81), and unemployed than employed (OR = 0.65; 95% CI: 0.47–0.92) individuals. MA users with anxiety and depression symptoms had significantly greater risk for MA-associated psychotic symptoms by 9.70 (6.92–13.59) and 1.90 (1.36–2.65) times respectively. Individuals with higher impulsivity were more likely to have MA-associated psychotic symptoms than those with lower (OR = 2.19; CI:1.50–3.20). Conclusion: MA-associated psychotic symptoms occurred frequently among MA users in China. The efforts that facilitate drug users' attempts to reduce MA use, abstain from poly-drug use, and control associated psychiatric symptoms and impulsivity should be supported because of their potential contribution to MA-associated psychotic symptoms in this population. |
format | Online Article Text |
id | pubmed-6194209 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-61942092018-10-26 Epidemiological Characteristics and Risk Factors of Methamphetamine—Associated Psychotic Symptoms Su, Meng-Fan Liu, Mo-Xuan Li, Jin-Qiao Lappin, Julia M. Li, Su-xia Wu, Ping Liu, Zhi-Min Shi, Jie Lu, Lin Bao, Yanping Front Psychiatry Psychiatry Objective: To explore the epidemiological characteristics and the risk factors for methamphetamine (MA)—associated psychotic symptoms among MA users in China. Methods: A cross-sectional study was conducted between April, 2012 and October, 2015 among individuals for whom MA was the principal drug of use in a Compulsory Drug Detoxification Center in Beijing, Guangdong Province. Demographic, drug use and psychological characteristics were examined using a specifically-designed questionnaire, the Positive and Negative Syndrome Scale, Barratt Impulsive Scale, Hamilton Anxiety Scale and Beck Depression Inventory. Logistic regression was performed to explore the risk factors for MA-associated psychotic symptoms. Results: A total of 1685 participants were included. Participants were predominantly aged 30 or above, unemployed, and were unmarried Han Chinese men, with limited education. The duration of MA use was more than 3 months in 72.3%. 47.8% reported that the dose of MA use was ≥ 0.2 g per occasion of use. 11.5% had used two or more synthetic drugs. The prevalence of MA-associated psychotic symptoms was 17.0% among MA users during periods of abstinence. Multiple logistic regression analyses showed that a higher dose (≥0.2 g per time), a longer duration of MA use (>3 months) a history of heroin use and a history of tobacco use were associated with MA-associated psychotic symptoms, with adjusted odds ratios (ORs) of 1.96 (95% confidence interval [CI]: 1.40–2.76), 1.98 (95% CI: 1.33–2.96) and 2.45 (95% CI: 1.67–3.60), 1.78 (95% CI: 1.27–2.49) respectively. MA-associated psychotic symptoms were less common among married/cohabitating than unmarried (OR = 0.56; 95% CI: 0.39–0.81), and unemployed than employed (OR = 0.65; 95% CI: 0.47–0.92) individuals. MA users with anxiety and depression symptoms had significantly greater risk for MA-associated psychotic symptoms by 9.70 (6.92–13.59) and 1.90 (1.36–2.65) times respectively. Individuals with higher impulsivity were more likely to have MA-associated psychotic symptoms than those with lower (OR = 2.19; CI:1.50–3.20). Conclusion: MA-associated psychotic symptoms occurred frequently among MA users in China. The efforts that facilitate drug users' attempts to reduce MA use, abstain from poly-drug use, and control associated psychiatric symptoms and impulsivity should be supported because of their potential contribution to MA-associated psychotic symptoms in this population. Frontiers Media S.A. 2018-10-12 /pmc/articles/PMC6194209/ /pubmed/30369888 http://dx.doi.org/10.3389/fpsyt.2018.00489 Text en Copyright © 2018 Su, Liu, Li, Lappin, Li, Wu, Liu, Shi, Lu and Bao. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Psychiatry Su, Meng-Fan Liu, Mo-Xuan Li, Jin-Qiao Lappin, Julia M. Li, Su-xia Wu, Ping Liu, Zhi-Min Shi, Jie Lu, Lin Bao, Yanping Epidemiological Characteristics and Risk Factors of Methamphetamine—Associated Psychotic Symptoms |
title | Epidemiological Characteristics and Risk Factors of Methamphetamine—Associated Psychotic Symptoms |
title_full | Epidemiological Characteristics and Risk Factors of Methamphetamine—Associated Psychotic Symptoms |
title_fullStr | Epidemiological Characteristics and Risk Factors of Methamphetamine—Associated Psychotic Symptoms |
title_full_unstemmed | Epidemiological Characteristics and Risk Factors of Methamphetamine—Associated Psychotic Symptoms |
title_short | Epidemiological Characteristics and Risk Factors of Methamphetamine—Associated Psychotic Symptoms |
title_sort | epidemiological characteristics and risk factors of methamphetamine—associated psychotic symptoms |
topic | Psychiatry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194209/ https://www.ncbi.nlm.nih.gov/pubmed/30369888 http://dx.doi.org/10.3389/fpsyt.2018.00489 |
work_keys_str_mv | AT sumengfan epidemiologicalcharacteristicsandriskfactorsofmethamphetamineassociatedpsychoticsymptoms AT liumoxuan epidemiologicalcharacteristicsandriskfactorsofmethamphetamineassociatedpsychoticsymptoms AT lijinqiao epidemiologicalcharacteristicsandriskfactorsofmethamphetamineassociatedpsychoticsymptoms AT lappinjuliam epidemiologicalcharacteristicsandriskfactorsofmethamphetamineassociatedpsychoticsymptoms AT lisuxia epidemiologicalcharacteristicsandriskfactorsofmethamphetamineassociatedpsychoticsymptoms AT wuping epidemiologicalcharacteristicsandriskfactorsofmethamphetamineassociatedpsychoticsymptoms AT liuzhimin epidemiologicalcharacteristicsandriskfactorsofmethamphetamineassociatedpsychoticsymptoms AT shijie epidemiologicalcharacteristicsandriskfactorsofmethamphetamineassociatedpsychoticsymptoms AT lulin epidemiologicalcharacteristicsandriskfactorsofmethamphetamineassociatedpsychoticsymptoms AT baoyanping epidemiologicalcharacteristicsandriskfactorsofmethamphetamineassociatedpsychoticsymptoms |